Cancer Immunotherapy with Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Journal of Crohn's & Colitis

• Publication date

  2016-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/ecco-jcc/jjv227PMID 26783344PMCID PMC4946758
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients

  2015cited by this paper
• Systematic review: colitis associated with anti‐CTLA‐4 therapy

  2015cited by this paper
• Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial.

  2015cited by this paper
• Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4

  2014cited by this paper
• Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial.

  2014cited by this paper
• A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer.

  2014cited by this paper
• Early-onset Crohn’s disease and autoimmunity associated with a variant in CTLA-4

  2014cited by this paper
• Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies

  2013cited by this paper
• Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma.

  2013cited by this paper
• Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial.

  2013cited by this paper
• A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C.

  2013cited by this paper
• Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells

  2013cited by this paper
• Aspirin, Nonsteroidal Anti-inflammatory Drug Use, and Risk for Crohn Disease and Ulcerative Colitis

  2012cited by this paper
• Safety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stage IV melanoma.

  2012cited by this paper
• CTLA-4 promotes Foxp3 induction and regulatory T cell accumulation in the intestinal lamina propria

  2012cited by this paper
• Management of immune-related adverse events and kinetics of response with ipilimumab.

  2012cited by this paper
• Phase I trial of tremelimumab in combination with short-term androgen deprivation in patients with PSA-recurrent prostate cancer

  2012cited by this paper
• Cutting Edge: Cell-Extrinsic Immune Regulation by CTLA-4 Expressed on Conventional T Cells

  2012cited by this paper
• Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study.

  2012cited by this paper
• Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.

  2011cited by this paper
• The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications.

  2010cited by this paper
• Improved survival with ipilimumab in patients with metastatic melanoma.

  2010cited by this paper
• Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma.

  2010cited by this paper
• Phase II Trial of Tremelimumab (CP-675,206) in Patients with Advanced Refractory or Relapsed Melanoma

  2010cited by this paper
• Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF.

  2009cited by this paper
• Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients

  2008cited by this paper
• Ipilimumab (Anti-CTLA4 Antibody) Causes Regression of Metastatic Renal Cell Cancer Associated With Enteritis and Hypophysitis

  2007cited by this paper
• The role of CD28 and cytotoxic T‐lymphocyte antigen‐4 (CTLA‐4) in regulatory T‐cell biology

  2006cited by this paper
• Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4.

  2006cited by this paper
• Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients

  2003cited by this paper
• The role of CTLA‐4 in the regulation of T cell immune responses

  1999cited by this paper
• CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation

  1995cited by this paper
• B70 antigen is a second ligand for CTLA-4 and CD28

  1993cited by this paper
• Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation.

  1993cited by this paper
• Effect of faecal stream diversion on recurrence of Crohn's disease in the neoterminal ileum.

  1991cited by this paper

• Clinical, Endoscopic, and Histological Characteristics of Severe Immune Checkpoint Inhibitor-Induced Colitis

  2026cites this paper
• Immune-mediated Colitis – An Update for Surgeons

  2025cites this paper
• Diagnostic Challenges in Enteropathies: A Histopathological Review

  2025cites this paper
• Complications digestives des traitements anticancéreux

  2025cites this paper
• Colon chaos: when drugs turn against your gut.

  2025cites this paper
• Role of Computed Tomography in Diagnosis of Colitis as a Complication of Cancer Therapy

  2025cites this paper
• Deep immune phenotyping reveals distinct immunopathogenesis in checkpoint inhibitor-induced colitis compared to ulcerative colitis.

  2025cites this paper
• Clinical perspective and treatment of immune-related colitis after cancer immunotherapy.

  2025cites this paper
• T Cell-Mediated Mechanisms of Immune-Related Adverse Events Induced by Immune Checkpoint Inhibitors.

  2025cites this paper
• Immune checkpoint inhibitor-related colitis in a patient with non-small cell lung cancer co-infected with HBV and EBV: a case report.

  2025cites this paper
• Incidence of and Risk Factors for Anti-PD-1/PD-L1- Associated Diarrhea and Colitis: A Retrospective Cohort Study of the Chinese Population

  2025cites this paper
• A Practical Approach in Differentiating IBD From Other Causes of Enterocolitis

  2025cites this paper
• Gastrointestinal complications of immune checkpoint Inhibitor therapy.

  2025cites this paper
• Risk factors for immune checkpoint inhibitor colitis: a retrospective multi-center cohort study using electronic health records

  2025cites this paper
• Early identification and multidisciplinary management of immune checkpoint inhibitors associated colitis can improve patient outcomes

  2025cites this paper
• Checkpoint inhibitor colitis: a gastroenterologists’ perspective

  2025cites this paper
• Mitigation strategies for gastrointestinal (GI) immune-related adverse events for patients with solid tumors receiving immunotherapy.

  2025cites this paper
• Immune checkpoint inhibitors: From friend to foe

  2025cites this paper
• De Novo Crohn's Disease 3 Years Following Immune Checkpoint Inhibitor Therapy

  2025cites this paper
• Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH-AEG-SEPD-SEOM-GETECCU.

  2024cites this paper
• Reconceptualization of immune checkpoint inhibitor-associated gastritis

  2024cites this paper
• Inflammatory Bowel Disease and Colorectal Cancer

  2024cites this paper
• Endoscopic findings of immune checkpoint inhibitor-related gastrointestinal adverse events

  2024cites this paper
• Immune-mediated colitis after immune checkpoint inhibitor therapy.

  2024cites this paper
• Sargramostim for Prophylactic Management of Gastrointestinal Immune-Related Adverse Events of Immune Checkpoint Inhibitor Therapy for Cancer

  2024cites this paper
• Systematic review of immune checkpoint inhibitor-related gastrointestinal, hepatobiliary, and pancreatic adverse events

  2024cites this paper
• The growing potential of tofacitinib in immune checkpoint inhibitor-induced colitis: identifying remaining puzzle pieces

  2024cites this paper
• New strategies in the diagnosis and treatment of immune-checkpoint inhibitor-mediated colitis

  2024cites this paper
• Management of infliximab refractory immune checkpoint inhibitor gastrointestinal toxicity: a multicenter case series

  2024cites this paper
• Corticosteroid-resistant immune-related adverse events: a systematic review

  2024cites this paper
• Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH-AEG-SEPD-SEOM-GETECCU.

  2024cites this paper
• PD-1/PD-L1 Inhibitor - Related Adverse Events and Their Management in Breast Cancer

  2024cites this paper
• Immune checkpoint inhibitor colitis, a rising issue in targeted cancer therapy era: A literature review

  2024cites this paper
• Chronic gastrointestinal immune-related adverse events in patients exposed to immune checkpoint inhibitors.

  2024cites this paper
• Anti-integrin αvβ6 autoantibodies are a potential biomarker for ulcerative colitis-like immune checkpoint inhibitor-induced colitis

  2024cites this paper
• Follow-Up Biopsies in Gastrointestinal Immune Checkpoint Inhibitor Toxicity May Show Markedly Different Inflammatory Patterns Than Initial Injury.

  2024cites this paper
• Uncovering the flip side of immune checkpoint inhibitors: a comprehensive review of immune-related adverse events and predictive biomarkers

  2024cites this paper
• Enterocolitis y otras manifestaciones de toxicidad gastrointestinal asociada a inmunoterapia y terapia blanco: una revisión para el gastroenterólogo

  2024cites this paper
• Enterocolitis and other immunotherapy and targeted therapy-related gastrointestinal manifestations: A review for gastroenterologist.

  2024cites this paper
• Update on immunotherapy‐mediated colitis: Clinical features, mechanisms, and management

  2024cites this paper
• Resolution of chronic inflammation and cancer.

  2024cites this paper
• Toxicity in the era of immune checkpoint inhibitor therapy

  2024cites this paper
• Treatment of immune checkpoint inhibitor-related colitis: a narrative review

  2024cites this paper
• Bifidobacterium modulation of tumor immunotherapy and its mechanism

  2024cites this paper
• Review article: Contemporary management of gastrointestinal, pancreatic and hepatic toxicities of immune checkpoint inhibitors

  2024cites this paper
• The role of gut microbiota and probiotics in preventing, treating, and boosting the immune system in colorectal cancer.

  2024cites this paper
• Histopathologic Features of Unmasked Inflammatory Bowel Disease Following Immune Checkpoint Inhibitor Therapy in Colon Biopsies

  2024cites this paper
• Histopathologic Manifestations of Immune Checkpoint Inhibitor Therapy-Associated Gastrointestinal Tract Injury: A Practical Review.

  2023cites this paper
• Fragmented antibodies in non-small cell lung cancer: a novel nano-engineered delivery system for detection and treatment of cancer.

  2023cites this paper
• Prognostic Value of Inflammatory Bowel Disease-associated Biomarkers in Patients With Immune Checkpoint Inhibitor Enterocolitis: A Retrospective Cohort Study.

  2023cites this paper
• Evaluation of appendectomy as a potential risk factor for immune checkpoint inhibitor-associated enterocolitis.

  2023cites this paper
• Immune mechanisms of toxicity from checkpoint inhibitors.

  2023cites this paper
• Immune mediated colitis: a surgical perspective

  2023cites this paper
• Adverse Effects of Immune-Checkpoint Inhibitors: A Comprehensive Imaging-Oriented Review

  2023cites this paper
• SOP Maßnahmen bei Diarrhö unter Therapie mit Checkpoint-Inhibitoren

  2023cites this paper
• Clostridium difficile infection and immune checkpoint inhibitor–induced colitis in melanoma: 18 cases and a review of the literature

  2023cites this paper
• Differenzialdiagnosen von Kolitiden

  2023cites this paper
• Microbiome alteration via fecal microbiota transplantation is effective for refractory immune checkpoint inhibitor–induced colitis

  2023cites this paper
• Gastrointestinal and Hepatobiliary Immune-related Adverse Events: A Histopathologic Review.

  2023cites this paper
• Checkpoint Inhibitor-Induced Colitis: An Update

  2023cites this paper
• Checkpoint Inhibitors: Limitations and Potential Strategies

  2023cites this paper
• The Optimal Management of Inflammatory Bowel Disease in Patients with Cancer

  2023influential citation
• Immune checkpoint inhibitors promising role in cancer therapy: clinical evidence and immune-related adverse events

  2023cites this paper
• A Brain, A Heart, and the Courage: Balancing Benefit and Toxicity of Immunotherapy in Melanoma.

  2023cites this paper
• Position statement on the management of the immune checkpoint inhibitor-induced colitis via multidisciplinary modified Delphi consensus.

  2023cites this paper
• [Drug induced gastro-intestinal tract lesions: A pathologist point of view].

  2023cites this paper
• Immunotherapy and Gastrointestinal Toxicities.

  2023cites this paper
• The colitis may be microscopic, but the diarrhea is not: update on the treatment of microscopic colitis and immune checkpoint inhibitor colitis

  2023cites this paper
• Antiplatelet drugs may increase the risk for checkpoint inhibitor-related pneumonitis in advanced cancer patients.

  2023cites this paper
• Shedding light on the side effects of immunotherapies used for leukemia: an updated review of the literature

  2023cites this paper
• Immune Checkpoint Inhibitors and Systemic Side Effects: Overview for the Inpatient Dermatologist

  2023cites this paper
• Recent Advances in the Development of Non-Invasive Imaging Probes for Cancer Immunotherapy.

  2023cites this paper
• Colitis induced by PD-1 inhibitor combined with platinum-containing dual drug chemotherapy in Lewis mice and its mechanism.

  2023cites this paper
• Serious immune‐related upper gastrointestinal toxicity of immune checkpoint inhibitors: a multicenter case series

  2023cites this paper
• Checkpoint Inhibitor-Induced Colitis: From Pathogenesis to Management

  2023influential citation
• Patients Undergoing Systemic Anti-Cancer Therapy Who Require Surgical Intervention: What Surgeons Need to Know

  2023cites this paper
• Refractory pembrolizumab immunotherapy-related colitis requiring biological therapy in an inactive HBcAb carrier

  2023cites this paper
• Clinical characteristics, diagnosis, treatment, and prognosis of nivolumab induced gastritis

  2023cites this paper
• Focus on Immune Checkpoint Inhibitors-related Intestinal Inflammation: From Pathogenesis to Therapeutical Approach

  2023cites this paper
• Endoscopic and histopathologic features of Anti‐PD‐1‐related collagenous colitis

  2022cites this paper
• A Review of Potential Role of Capsule Endoscopy in the Work-Up for Chemotherapy-Induced Diarrhea

  2022cites this paper
• Noninvasive Prediction of Outcomes in Autoimmune Hepatitis–Related Cirrhosis

  2022cites this paper
• Chronic Use of Proton Pump Inhibitors Is Associated With an Increased Risk of Immune Checkpoint Inhibitor Colitis in Renal Cell Carcinoma.

  2022cites this paper
• Dietary Considerations for Inflammatory Bowel Disease Are Useful for Treatment of Checkpoint Inhibitor-Induced Colitis

  2022cites this paper
• Germline genetic variation and predicting immune checkpoint inhibitor induced toxicity

  2022cites this paper
• Implementing an immunotherapy toxicity (IOTOX) GI service improves outcomes in patients with immune-mediated diarrhea and colitis

  2022cites this paper
• Histological Features of Celiac-Disease-like Conditions Related to Immune Checkpoint Inhibitors Therapy: A Signal to Keep in Mind for Pathologists

  2022cites this paper
• Update on Immune Checkpoint Inhibitor Enterocolitis

  2022cites this paper
• Reactivaion of immune-related colitis during targeted therapy in a patient with metastatic cutaneous melanoma

  2022cites this paper
• Oral beclomethasone dipropionate is an effective treatment for immune checkpoint inhibitor induced colitis

  2022cites this paper
• Immune checkpoint inhibitor gastritis is often associated with concomitant enterocolitis, which impacts the clinical course

  2022cites this paper
• A case of refractory immune checkpoint inhibitor‐induced colitis with Clostridioides difficile infection

  2022cites this paper
• Late-onset toxicities of monoclonal antibodies in cancer patients.

  2022cites this paper
• Immune Checkpoint inhibitor Enterocolitis vs Idiopathic Inflammatory Bowel Disease.

  2022cites this paper
• Immune checkpoint Inhibitor-Induced diarrhea and Colitis: Incidence and Management. A systematic review and Meta-analysis.

  2022cites this paper
• Improving cancer immunotherapy via co-delivering checkpoint blockade and thrombospondin-1 downregulator

  2022cites this paper
• Leveraging structural and 2D-QSAR to investigate the role of functional group substitutions, conserved surface residues and desolvation in triggering the small molecule-induced dimerization of hPD-L1

  2022cites this paper
• Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.

  2022cites this paper
• Risk factors and predictors of immune-related adverse events: implications for patients with non-small cell lung cancer

  2022cites this paper
• Immunotherapy for Cancer: Common Gastrointestinal, Liver, and Pancreatic Side Effects and Their Management

  2022influential citation